» Articles » PMID: 30326932

Protocol and Methods for Testing the Efficacy of Well-being Therapy in Chronic Migraine Patients: a Randomized Controlled Trial

Overview
Journal Trials
Publisher Biomed Central
Date 2018 Oct 18
PMID 30326932
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic migraine is a chronic medical condition associated with resistance to pharmacological treatment and poor benefits from the psychological interventions studied to date, including acceptance and commitment therapy or mindfulness. This manuscript describes the rationale and methods for a pilot feasibility study designed to (1) establish and (2) evaluate the feasibility and acceptability of research procedures and interventions to investigate whether well-being therapy improves outcomes relative to a control condition.

Methods: The current intervention will use a randomized controlled trial design, wherein 30 outpatients with chronic migraine will be randomized (1:1) to well-being therapy (n = 15) or to a control condition (n = 15). Primary outcomes include the level of disability caused by migraine and the frequency, duration, and intensity of migraine attacks; the secondary outcomes focus on anxiety, depression, psychological well-being, euthymia, and distress. Primary and secondary outcomes will be assessed at baseline, after sessions 4 and 8, and at 3-month follow-up. The Ethical Review Boards at the University-Hospital Careggi has approved the study (5th December 2017).

Discussion: Identifying medium-term interventions able to improve chronic migraine is relevant to manage this illness. The present randomized trial might represent a step forward for managing chronic migraine by means of psychological interventions.

Trial Registration: ClinicalTrial.gov Identifier: NCT03404336 . Registered on 19 January 2018.

Citing Articles

The Effect of the Rice Endosperm Protein Hydrolysate on the Subjective Negative Mood Status in Healthy Humans: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial.

Nakayama R, Nishi D, Sato M, Ito A, Uchiyama K, Higuchi Y Nutrients. 2023; 15(15).

PMID: 37571427 PMC: 10421398. DOI: 10.3390/nu15153491.


Well-being Therapy in Depressive Disorders.

Mansueto G, Cosci F Adv Exp Med Biol. 2021; 1305:351-374.

PMID: 33834409 DOI: 10.1007/978-981-33-6044-0_19.

References
1.
Chan A, Tetzlaff J, Gotzsche P, Altman D, Mann H, Berlin J . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013; 346:e7586. PMC: 3541470. DOI: 10.1136/bmj.e7586. View

2.
Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L . Topiramate in the treatment of chronic migraine. Cephalalgia. 2003; 23(8):820-4. DOI: 10.1046/j.1468-2982.2003.00592.x. View

3.
Fava G, Kellner R, Perini G, Fava M, Michelacci L, Munari F . Italian validation of the Symptom Rating Test (SRT) and Symptom Questionnaire (SQ). Can J Psychiatry. 1983; 28(2):117-23. DOI: 10.1177/070674378302800208. View

4.
Stewart W, Lipton R, Dowson A, Sawyer J . Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56(6 Suppl 1):S20-8. DOI: 10.1212/wnl.56.suppl_1.s20. View

5.
Penzien D, Andrasik F, Freidenberg B, Houle T, Lake 3rd A, Lipchik G . Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup. Headache. 2005; 45 Suppl 2:S110-32. DOI: 10.1111/j.1526-4610.2005.4502004.x. View